Skip to main content
. 2015 Apr 1;125(25):3878–3885. doi: 10.1182/blood-2015-01-623447

Figure 1.

Figure 1

Trial design of AML17. Patients allocated either CEP-701 or everolimus post–course 1 carried this molecule forward into subsequent courses. *After closure of the CEP-701 randomization, patients were guided by risk score to either poor risk or not poor risk options. **After closure of the everolimus randomization, patients in this group received daunorubicin (DA) 50 mg alone. ***After closure of the D clofarabine arm, patients were recommended to receive FLAG-Ida (which was also the case if renal criteria were not met).